What Digital Artefacts does

Digital Artefacts is a US-based custom technology services firm headquartered in Iowa City. Founded in 2000, the company specializes in developing web and mobile applications, Internet of Things (IoT) solutions, wearable electronics, and virtual/augmented reality (VR/AR) experiences. The company is structured as a private for-profit entity and operates with a headcount of 101-250 employees, with Joan Severson listed as co-founder and president.

Based on the available input data, the company's business model centers on custom development services across these emerging technology domains. No further details on revenue model, pricing mechanics, go-to-market motion, customer composition, or competitive positioning are disclosed in the source material. Twenty-four-plus years of continuous operation since 2000 indicates an established services firm in the custom development space, but the lack of disclosed operational, financial, or customer data makes a fuller characterization of the business infeasible from this input alone. The data is insufficient to assess product depth, technology stack, partnerships, geographic footprint, or revenue trajectory.

Name

Digital Artefacts

Website

https://digitalartefacts.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

101–250 employees

Short description

Digital Artefacts is a US-based custom technology services firm founded in 2000 and headquartered in Iowa City, building web and mobile applications, IoT solutions, wearable electronics, and VR/AR experiences for clients across emerging technology domains.

Ownership category

akta.pro rank

Headquarters

HQ city

Iowa City

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Clinical Trial eSource Solutions: Clinical Ink provides eSource platform solutions including Direct Data Capture, eCOA, eConsent, and related technologies to pharmaceutical sponsors and CROs for clinical trial data management. Revenue is generated through software licensing and services for clinical trials across various phases and therapeutic areas.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Digital Artefacts is a custom technology development firm that designs and delivers web applications, mobile applications, Internet of Things (IoT) solutions, wearable electronics, and virtual reality/augmented reality (VR/AR) experiences for client projects. The firm operates as a multi-disciplinary development partner combining software and hardware expertise under one organization.

Product overview

Clinical Ink offers a unified eSource ecosystem platform designed for decentralized clinical trials. The platform integrates Direct Data Capture (DDC) technology and electronic Clinical Outcome Assessments (eCOA) for capturing clinical trial data. The core platform is supported by specialized modules including GlucoseReady™ (for diabetes/obesity trials with CGM integration), SPUR™ (adherence solution), Kaitality™ (weight management), eLAS® Suite (lupus trials), eConsent, Televisit, Sensors & Wearables, Digital Biomarkers, TrialLens™, and EDCXtra™. The ecosystem is designed to ingest data from multiple sources regardless of how it was captured, facilitating decentralized trials and shifting towards capturing data directly from patients.

Differentiator

Problem solved

Functional benefit

Products and services

• Web Application Development Design, engineering, and delivery of custom web applications for business clients.
• Mobile Application Development Design and development of custom mobile applications for business clients across iOS and Android platforms.
• IoT Development Design and development of Internet of Things (IoT) solutions, including connected devices and integrated systems for business clients.
• Wearable Electronics Development Design and engineering of wearable electronic devices and products for client projects.
• VR/AR Development Design and development of virtual reality (VR) and augmented reality (AR) experiences and applications for business clients.

Quantifiable outcome

• Study build timeline reduced to 10 days
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature12 records

Partnerships

One partnership is on record.

• Tandem Diabetes CarecoreTechnology or Integration · 1 December 2025Clinical Ink announced collaboration with Tandem Diabetes Care to integrate Automated Insulin Delivery data into the GlucoseReady connected device software platform, enabling seamless data flow for diabetes clinical trials.

Scale indicators4 records

Broad incumbents

• Medidata (Dassault Systèmes): Medidata offers the Rave eCOA, EDC, and decentralized trial platform used by most large pharmaceutical sponsors. It is a broad incumbent with overlapping DDC, eCOA, and DCT capabilities, making it Clinical Ink's most significant scale competitor.
• Veeva Systems: Veeva provides the Vault CDB and Vault EDC suite, including eCOA, CTMS, and study-startup tools for life sciences. It is a broad incumbent with deep enterprise relationships that overlap directly with Clinical Ink's sponsor and CRO target accounts.
• IQVIA (Oracle Clinical One): IQVIA operates the Oracle Clinical One platform spanning EDC, eCOA, RTSM, and DCT, in addition to CRO services. It is a broad incumbent competing on integrated platform breadth and deep pharma relationships.

Direct peers

• Signant Health: Signant Health (formed from CRF Health and Bracket) provides eCOA, eConsent, patient engagement, and DCT solutions to pharma and CROs. It is a direct peer with a near-identical product set in eCOA, eConsent, sensors, and Televisit-style remote engagement.
• Medrio: Medrio offers EDC, eCOA, and DCT solutions for clinical trials with a focus on mid-market and academic sponsors. It is a direct peer competing for the same sponsor and CRO customers on EDC and eCOA build speed.
• ERT (now Clario): Clario (formerly ERT) provides eCOA, cardiac safety, imaging, and digital biomarker solutions for clinical trials. It is a direct peer with strong overlap in eCOA, digital biomarkers, and DCT offerings to global pharma sponsors.

Emerging players

• Castor: Castor provides an EDC and ePRO platform for clinical trials, including DCT modules and patient-centric data capture. It is an emerging player with overlapping eCOA, eConsent, and remote data capture capabilities aimed at sponsors and CROs.
• Y-Prime: Y-Prime offers eCOA, IRT, and clinical supply solutions for clinical trials, with particular focus on eCOA build speed and patient-centric design. It is an emerging player with a directly comparable eCOA product and a similar mid-tier sponsor customer base.
• Curebase: Curebase offers a DCT platform including eCOA, eConsent, telehealth, and remote patient engagement tools for sponsors and CROs. It is an emerging player with overlapping Televisit, eConsent, and eCOA functionality aimed at decentralized studies.
• ObvioHealth: ObvioHealth is a DCT-focused CRO with an integrated eCOA, eConsent, Televisit, and sensor platform. It is an emerging player that competes for the same sponsor-led decentralized study budgets that Clinical Ink targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat1 record

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@ClinicalInk1
• LinkedInlinkedin.com/company/clinical-ink
• Xx.com/DigArtefact

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Digital Artefacts